Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast.

Trial Profile

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2012

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 May 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record NCT00496808).
    • 12 May 2009 Planned number of patients changed from 20 to 71 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top